Patria Private Equity Trust plc
Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13
8 January 2025
ESTIMATED NET ASSET VALUE AT 30 NOVEMBER 2024
Patria Private Equity Trust plc ("PPET" or "the Company") announces its estimated net asset value ("NAV") at 30 November 2024
· Estimated NAV at 30 November 2024 was
· Excluding new investments, 98.0% by value of portfolio dated 30 September 2024 (estimated NAV at 31 October 2024 was 99.3% dated 30 June 2024)
· PPET received
· Outstanding commitments of
· Short term resources (cash balances, deferred consideration and undrawn credit facilities) were £325.6 million as at 30 November 2024
Estimated NAV
At 30 November 2024, PPET's estimated NAV was
The 2.3% constant currency uplift in valuations was due to a broad increase across the portfolio. PPET's primary fund, secondary and direct investment portfolios increased 2.2%, 2.8% and 2.2% in constant currency respectively over the quarter.
In terms of underlying portfolio companies, there were notable quarterly valuation uplifts of:
· Wundex (wound care management business);
· Action (non-food discount retailer);
· CDL (provider of comprehensive cardiac PET and nuclear medicine delivery solutions); and
· Chanelle Pharma (manufacturer of generic animal and human health products).
Drawdowns and distributions
PPET received
Drawdowns were made across several of PPET's fund investments, primarily to fund new underlying portfolio company investments and management fees. Notable drawdowns in the portfolio during the month included:
· Nordic Capital Evolution Fund (
· CVC Fund VII (
· Hg Mercury 4 (
The distributions received generated realised gains and income of
· Sunbelt (a leading modular manufacturer and designer of commercial custom and fleet building solutions) by MSouth Equity Partners IV;
· Zabka (a leading convenience retailer in
· CDL (provider of comprehensive cardiac PET and nuclear medicine delivery solutions) by Excellere which resulted in the partial realisation of PPET's direct investment position.
Investment activity
There were no new commitments to announce from the month of November.
Commitments
The Company had
Credit facility and cash balances
The Company has a
In addition, the Company had cash balances of
Share Buybacks
Pursuant to the Company's share buyback programme, the Company bought back 245,000 ordinary shares into treasury during November 2024.
For further information please contact:
Patria Private Equity Trust plc |
PPET.InvestorRelations@patria.com |
Alan Gauld (Lead Manager) Amber Sarafilovic (Marketing & Investor Relations) |
|
Paul Evitt (Company Secretary)
|
|
Investec Bank plc |
+44 (0)20 7597 4000 |
Lucy Lewis |
|
Tom Skinner |
|
Denis Flanagan
|
|
SEC Newgate |
+44 (0)20 3757 6872 |
Sally Walton |
PPET@secnewgate.co.uk |
Notes:-
Patria Private Equity Trust plc is an investment company managed by Patria Capital Partners LLP, the ordinary shares of which are admitted to listing by the
Additional detail about PPET's NAV and investment diversification can be found on PPET's website (www.patriaprivateequitytrust.com). Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website is incorporated into, or forms part of, this announcement.
[1] PPET's valuation policy for private equity funds and direct investments is based on the latest valuations reported by the managers of the funds and direct investments in which the Company has interests. At 30 November 2024, excluding new investments, 98.0% of the portfolio valuations were dated 30 September 2024. The value of the portfolio is therefore calculated as the 30 September 2024 valuation, adjusted for subsequent cashflows over the period to 30 November 2024.
This is an update from the estimated NAV at 31 October 2024, whereby 99.3% of the portfolio valuations, excluding new investments, were dated 30 June 2024, adjusted for subsequent cashflows over the period to 31 October 2024.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.